Dr. Wendy (Wei) Zhang is the Vice President of Alliance Operations, Shanghai EXUMA Biotech where she serves as a site liaison, facilitates infrastructure build out, and manages the operations of the preclinical research team. Previously, she was in charge of operations for the F1-Bioduro team from June 2016 until April 2019, and had been the Head of Biologics at BioDuro since Dec 2015. Prior to that, she was the Director of Biologics Discovery at HD Biosciences (now a Wuxi Apptec company) from April 2013 to Nov 2015, where she was responsible for all therapeutic antibody discovery related business utilizing their phage display platform and also leading the team for new technology platform development. From 2008 to 2013, Dr. Zhang was a Preclinical Assay Development Scientist at aTyr Pharma Inc. (IPO in 2015) in San Diego, California. She served as the key scientist leading the in vitro assay development efforts while exploring the MOAs for novel therapeutic Physiocrines. She was also responsible for establishing SOPs of release assays using human primary cells and tissues for leading candidates and evaluating CROs in Asia. Dr. Zhang came to San Diego for her postdoctoral training at the Scripps Research Institute, La Jolla in 2004, after she earned her PhD in Molecular Microbiology from the Chinese Academy of Sciences.